{"id":702948,"date":"2024-06-17T17:36:01","date_gmt":"2024-06-17T17:36:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=702948"},"modified":"2024-06-17T17:36:01","modified_gmt":"2024-06-17T17:36:01","slug":"myelofibrosis-pipeline-insights-2024-clinical-trials-latest-approvals-treatment-options-therapies-key-companies-geron-corporation-merck-telios-pharma-ryvu-therapeutics-sa-taiga-biotechnolo","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/myelofibrosis-pipeline-insights-2024-clinical-trials-latest-approvals-treatment-options-therapies-key-companies-geron-corporation-merck-telios-pharma-ryvu-therapeutics-sa-taiga-biotechnolo_702948.html","title":{"rendered":"Myelofibrosis Pipeline Insights 2024 | Clinical Trials, Latest Approvals, Treatment Options, Therapies, Key Companies | Geron Corporation, Merck, Telios Pharma, Ryvu Therapeutics SA, Taiga Biotechnolo"},"content":{"rendered":"
\n
\"Myelofibrosis<\/a><\/div>\n
\n
Myelofibrosis Pipeline Insights 2024<\/div>\n<\/div>\n<\/div>\n
\u201cMyelofibrosis Pipeline Insight, 2024\u201d report by DelveInsight outlines a comprehensive assessment of the present clinical\/non-clinical development activities and growth prospects across the Myelofibrosis Market.<\/div>\n

DelveInsight’s “Myelofibrosis – Pipeline Insight, 2024<\/a><\/strong>,” report provides comprehensive insights about 35+ companies and 40+ pipeline drugs in the Myelofibrosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n

Some of the key players such as Geron (Imetelstat), AbbVie (Navitoclax), Sierra Oncology (Momelotinib), Incyte Corporation (Parsaclisib), Celgene\/BMS (Luspatercept-aamt), MorphoSys (Pelabresib), Imago Biosciences (Bomedemstat), Pharmaxis (PXS-5505), and others are evaluating their lead candidates in different stages of clinical development.<\/p>\n

According to DelveInsight, the market for therapeutics in Myelofibrosis is poised for significant growth in the coming years. This growth is driven by increasing cases of Myelofibrosis, extensive research and development efforts by pharmaceutical companies, and the anticipated introduction of new pipeline therapies. Emerging treatments are exploring diverse mechanisms beyond JAK inhibitors, such as imetelstat (a telomerase inhibitor), navitoclax (an inhibitor of BCL-XL\/BCL-2), GB2064 (inhibitors of LOXL2 protein), navtemadlin (an inhibitor of MDM2 protein), pelabresib (a BET inhibitor), among others. These therapies aim to address the needs of patients who are refractory or have relapsed after JAK inhibitor treatment, offering alternative therapeutic options.<\/p>\n

Myelofibrosis Overview<\/strong><\/p>\n

Myelofibrosis is a rare form of chronic leukemia characterized by abnormal blood cell production in the bone marrow, leading to extensive fibrosis (scarring). This disrupts the marrow’s ability to produce red blood cells, causing severe anemia, weakness, and fatigue. Additional symptoms include enlarged spleen (splenomegaly), night sweats, fever, and bone pain. As the disease progresses, complications such as bleeding and increased susceptibility to infections arise due to impaired white blood cell function. Myelofibrosis belongs to a group of disorders called myeloproliferative neoplasms, characterized by excessive production of blood cells.<\/p>\n

The exact cause of myelofibrosis remains unclear, but it often involves mutations in genes like JAK2, CALR, or MPL. These mutations disrupt normal cell signaling pathways, leading to abnormal cell growth and fibrosis. Diagnosis typically involves blood tests, bone marrow biopsy, and genetic testing to identify these mutations. Treatment focuses on symptom management and improving quality of life, including medications such as JAK inhibitors, blood transfusions, and potentially stem cell transplantation in certain cases. Prognosis varies widely, depending on factors such as symptom severity, age, and overall health, with some patients living for many years after diagnosis while others experience faster disease progression.<\/p>\n

Diagnostic techniques require complete blood cell counts, bone marrow analysis, extensive genetic evaluations, and a comprehensive patient history. Molecular drivers like JAK2V617F, CALR, and MPL mutations are prevalent, with approximately 8% to 10% of cases being “triple-negative.” Additional genetic variants are observed in about 80% of patients. Current clinical and molecular scoring systems help predict survival and guide treatment decisions, including eligibility for stem cell transplantation and participation in clinical trials. Standard treatments focus on managing anemia, utilizing drugs like hydroxyurea and JAK inhibitors such as ruxolitinib, fedratinib, and pacritinib. Approximately 42% of ruxolitinib-treated patients achieve a spleen volume reduction of 35% or greater by week 24, along with similar outcomes observed with other JAK inhibitors.<\/p>\n

The Myelofibrosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.<\/p>\n

Myelofibrosis Pipeline Analysis<\/strong><\/p>\n

The report provides insights into: <\/strong><\/p>\n

The report provides detailed insights into the emerging therapies for the treatment of Myelofibrosis and the aggregate therapies developed by major pharma companies.<\/p>\n